Characteristics | UPA 15 mg (n=303) | ABA IVa (n=309) |
---|---|---|
Age, mean ± SD | 55.3 ± 11.4 | 55.8 ± 11.9 |
Female, n (%) | 249 (82) | 253 (82) |
White, n (%) | 288 (95) | 285 (92) |
Duration of RA diagnosis, mean ± SD | 12.4 ± 9.5 | 11.8 ± 8.3 |
Number of prior bDMARDs received, n (%) | ||
 1 | 206 (68) | 202 (65) |
 2 | 64 (21) | 70 (23) |
 ≥3 | 29 (10) | 35 (11) |
Number of prior TNF inhibitors received, n (%) | ||
 0 | 40 (13) | 36 (12) |
 1 | 212 (70) | 198 (64) |
 2 | 38 (13) | 64 (21) |
 3 | 13 (4) | 10 (3) |
 ≥4 | 0 | 1 (0.3) |
Concomitant csDMARDs at baseline, n (%) | ||
 MTX alone | 223 (74) | 215 (70) |
 MTX and other csDMARD | 30 (10) | 38 (12) |
 csDMARD other than MTX | 45 (15) | 56 (18) |
Oral steroid at baseline, n (%) | 169 (56) | 158 (51) |